After confirmation by a professional pathologist, we assessed the paxillin expression levels in all breast cancer tissues and defined four levels as shown in Figure 1A. Subsequently, we divided patients into two groups according to their H-score: a paxillin-high group and a paxillin-low group, and compared the overall survival and recurrence-free survival of the two groups. Here, PXN is linked to breast cancer.